Now loading...
JM Financial has upgraded Aster DM Healthcare to a BUY rating with a revised target price of Rs 532. The brokerage highlights Aster’s valuation gap compared to peers and expects synergies from the Aster-QCIL merger to drive revenue growth. They anticipate a significant improvement in EBITDA and RoIC, projecting a 34% upside for the stock.
Now loading...